» Articles » PMID: 22802095

The MAPT H1 Haplotype is Associated with Tangle-predominant Dementia

Overview
Specialty Neurology
Date 2012 Jul 18
PMID 22802095
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Tangle-predominant dementia (TPD) patients exhibit cognitive decline that is clinically similar to early to moderate-stage Alzheimer disease (AD), yet autopsy reveals neurofibrillary tangles in the medial temporal lobe composed of the microtubule-associated protein tau without significant amyloid-beta (Aβ)-positive plaques. We performed a series of neuropathological, biochemical and genetic studies using autopsy brain tissue drawn from a cohort of 34 TPD, 50 AD and 56 control subjects to identify molecular and genetic signatures of this entity. Biochemical analysis demonstrates a similar tau protein isoform composition in TPD and AD, which is compatible with previous histological and ultrastructural studies. Further, biochemical analysis fails to uncover elevation of soluble Aβ in TPD frontal cortex and hippocampus compared to control subjects, demonstrating that non-plaque-associated Aβ is not a contributing factor. Unexpectedly, we also observed high levels of secretory amyloid precursor protein α (sAPPα) in the frontal cortex of some TPD patients compared to AD and control subjects, suggesting differences in APP processing. Finally, we tested whether TPD is associated with changes in the tau gene (MAPT). Haplotype analysis demonstrates a strong association between TPD and the MAPT H1 haplotype, a genomic inversion associated with some tauopathies and Parkinson disease (PD), when compared to age-matched control subjects with mild degenerative changes, i.e., successful cerebral aging. Next-generation resequencing of MAPT followed by association analysis shows an association between TPD and two polymorphisms in the MAPT 3' untranslated region (UTR). These results support the hypothesis that haplotype-specific variation in the MAPT 3' UTR underlies an Aβ-independent mechanism for neurodegeneration in TPD.

Citing Articles

Amyloid-β predominant Alzheimer's disease neuropathologic change.

Kovacs G, Katsumata Y, Wu X, Aung K, Fardo D, Forrest S Brain. 2024; 148(2):401-407.

PMID: 39417691 PMC: 11788189. DOI: 10.1093/brain/awae325.


MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy.

Ressler H, Humphrey J, Vialle R, Babrowicz B, Kandoi S, Raj T Acta Neuropathol Commun. 2024; 12(1):135.

PMID: 39154163 PMC: 11330133. DOI: 10.1186/s40478-024-01839-3.


Prevalence and clinicopathological features of primary age-related tauopathy (PART): A large forensic autopsy study.

Yoshida K, Hata Y, Ichimata S, Tanaka R, Nishida N Alzheimers Dement. 2024; 20(8):5411-5420.

PMID: 38938196 PMC: 11350034. DOI: 10.1002/alz.14037.


The clinical importance of suspected non-Alzheimer disease pathophysiology.

Vos S, Delvenne A, Jack Jr C, Thal D, Visser P Nat Rev Neurol. 2024; 20(6):337-346.

PMID: 38724589 DOI: 10.1038/s41582-024-00962-y.


Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.

Langerscheidt F, Wied T, Kabbani M, van Eimeren T, Wunderlich G, Zempel H J Neurol. 2024; 271(6):2992-3018.

PMID: 38554150 PMC: 11136742. DOI: 10.1007/s00415-024-12314-3.


References
1.
Trojanowski J, Vandeerstichele H, Korecka M, Clark C, Aisen P, Petersen R . Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010; 6(3):230-8. PMC: 2867838. DOI: 10.1016/j.jalz.2010.03.008. View

2.
Devanand D, Mikhno A, Pelton G, Cuasay K, Pradhaban G, Dileep Kumar J . Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol. 2010; 23(3):185-98. PMC: 3110668. DOI: 10.1177/0891988710363715. View

3.
Mirra S, HEYMAN A, McKeel D, SUMI S, Crain B, Brownlee L . The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991; 41(4):479-86. DOI: 10.1212/wnl.41.4.479. View

4.
Aronov S, Aranda G, Behar L, Ginzburg I . Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. J Neurosci. 2001; 21(17):6577-87. PMC: 6763080. View

5.
Ghebranious N, Ivacic L, Mallum J, Dokken C . Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res. 2005; 33(17):e149. PMC: 1243648. DOI: 10.1093/nar/gni155. View